Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response. Objectives The Accelerating Medicines Partnership® Parkinson's Disease (AMP PD) program is a public–private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non‐profit organizations, managed by the Foundation for National Institutes of Health (FNIH). The program aims to advance the molecular and clinical characterization of PD through deep, longitudinal profiling of patient data and biosamples, with the goal of identifying and validating diagnostic, prognostic, and progression biomarkers for PD. Methods Longitudinal proteomic profiling, both targeted and untargeted, was performed on cerebrospinal fluid (CSF) and plasma samples. The resulting datasets are publicly accessible via the AMP® PD Knowledge Platform. Results The proteomic datasets enable differential protein analyses and can be used to explore molecular alterations associated with PD progression and heterogeneity. Conclusions These studies contribute to the broader AMP PD initiative by providing the research community with a harmonized proteomics dataset. As part of the larger AMP PD data, this work provides the PD community with a harmonized and accessible proteomics dataset that can be utilized for discovery, hypothesis generation, and validation of users’ own research. © 2026 Technome. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Dardov et al. (Thu,) studied this question.